Skip to main content
Figure 2 | BMC Medicine

Figure 2

From: No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over

Figure 2

Estimates of the frailty specific log hazard ratio for treatment effect (active treatment versus placebo) and point-wise 95% confidence limits versus baseline frailty index, adjusted for age and sex and stratified by region of recruitment. (a) Fatal and non-fatal strokes. (b) Fatal and non-fatal cardiovascular events. (c) Total mortality.

Back to article page